Histamine H
3
receptors (H
3
R) antagonists/inverse agonists are becoming a promising therapeutic approach for epilepsy. In this article, novel nonimidazole H
3
R antagonists/inverse agonists have been designed and synthesised
via
hybriding the H
3
R pharmacophore (aliphatic amine with propyloxy chain) with the 1,2,4-triazole moiety as anticonvulsant drugs. The majority of antagonists/inverse agonists prepared here exerted moderate to robust activities in cAMP-response element (CRE) luciferase screening assay. 1-(3-(4-(3-Phenyl-4
H
-1,2,4-triazol-4-yl)phenoxy)propyl)piperidine (
3l
) and 1-(3-(4-(3-(4-chlorophenyl)-4
H
-1,2,4-triazol-4-yl)phenoxy)propyl)piperidine (
3m
) displayed the highest H
3
R antagonistic activities, with IC
50
values of 7.81 and 5.92 nM, respectively. Meanwhile, the compounds with higher H
3
R antagonistic activities exhibited protection for mice in maximal electroshock seizure (MES)-induced convulsant model. Moreover, the protection of
3m
against the MES induced seizures was fully abrogated when mice were co-treated with RAMH, a CNS-penetrant H
3
R agonist, which suggested that the potential therapeutic effect of
3m
was through H
3
R. These results indicate that the attempt to find new anticonvulsant among H
3
R antagonists/inverse agonists is practicable.